Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Nov 20, 2019

Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence
Nov 6, 2019

New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders

*Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma
Nov 6, 2019

New data for isatuximab in multiple myeloma to be presented at ASH 2019
Nov 5, 2019

Provention Bio Reports Third Quarter 2019 Financial Results

- PRV-031 (teplizumab) Granted Breakthrough Therapy and PRIME Designations -
Nov 4, 2019

FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

* Will be available in fall 2020, in time for the 2020-2021 flu season
Nov 4, 2019

Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
Oct 31, 2019

Sanofi Q3 well on track
- Video 1
- Photos 4
Oct 29, 2019

Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019
Oct 24, 2019

Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
Oct 22, 2019

Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease

-Study Did Not Achieve Primary Endpoint Due to High Placebo Effect-

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.